Sanofi-Aventis (France) Sticks to $69 Per Share Genzyme Corporation Offer

September 9, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Wall Street Journal -- PARIS (Dow Jones)--French pharmaceuticals giant Sanofi-Aventis SA (SNY.FR) said Thursday it hasn't made any offers to acquire U.S. biotech group Genzyme Corp. (GENZ) other than its standing all-cash bid of $69 a share.

Twitter
LinkedIn
Facebook
Email
Print

Mergers & acquisitions Europe

Sanofi